Interv Akut Kardiol. 2010;9(1):20-26

Alcohol septal ablation vs. surgical myectomy in the treatment of hypertrophic obstructive cardiomyopathy

Miloslav Brtko1, Jan Vojáček1, Josef Šťásek2, Jan Vojáček2, Pavel Polanský1, Martin Tuna1, Josef Bis2, Jaroslav Dušek2
1 Kardiocentrum, Kardiochirurgická klinika LF UK a FN, Hradec Králové
2 I. interní klinika, LF UK a FN, Hradec Králové

Hypertrophic cardiomyopathy is an autosomal dominant disease with prevalence of 0,2 % and with asymetric hypertrophy of left ventricle

(> 15 mm). Obstructive form is clinically more significant and has worse prognosis. As a cause of this disease more than 200 mutations on

more than 10 genes were diagnosed till now. Symptomatology and prognosis of hypertophic cardiomyopathy is heterogenous – from

asymptomatic course to sudden death. Angina pectoris, effort dyspnoe or syncope are the most common symptoms. Mortality is estimated

1 % to 6 %. Obstructive form is characterized by resting or provoked gradient > 30 mm Hg. In patients with obstructive form the risk

of death, stroke and heart failure is higher as well as the risk of disease progression into the NYHA class III or IV. In the treatment of this

disease drugs, A-V sequential stimulation, surgical myectomy or alcohol septal ablation (ASA) are used. The most effective treatment of

obstructive form are surgical myectomy and ASA. Both methods are connected with low mortality, both procedures significantly improve

symptomatology of the patients, surgical myectomy improves patient´s prognosis. Lowering of resting and provoked gradients, favourable

remodeling of the left ventricle and the left atrium, decreasing of the severity of SAM and increasing of effort tolerance are seen during

follow-up. A-V block with permanent pacemaker implantation and right bundle branch block are more common after ASA, left bundle

branch block is more common after surgical myectomy. Aortic valve insufficiency, atrial fibrilation and stroke are sparse complications of

surgical myectomy. ASA is performed more often in older polymorbid patients, surgical myectomy in younger patients with associated

aortic or mitral valve disease. The principles and comparison of both methods from many perspectives are given in this review.

Keywords: hypertrophic cardiomyopathy, alcohol septal ablation, septal myectomy

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brtko M, Vojáček J, Šťásek J, Vojáček J, Polanský P, Tuna M, et al.. Alcohol septal ablation vs. surgical myectomy in the treatment of hypertrophic obstructive cardiomyopathy. Interv Akut Kardiol. 2010;9(1):20-26.
Download citation

References

  1. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4,111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92: 785-789. Go to original source... Go to PubMed...
  2. Maron MS, Zenovich AG, Casey SA, et al. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol 2005; 95: 1329-1333. Go to original source... Go to PubMed...
  3. Maron BJ, Casey SA, Polic LC, et al. Clinical course of hypertophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-656. Go to original source... Go to PubMed...
  4. Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350(13): 1320-1327. Go to original source... Go to PubMed...
  5. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-373. Go to original source... Go to PubMed...
  6. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42: 1687-1713. Go to original source... Go to PubMed...
  7. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303. Go to original source... Go to PubMed...
  8. Šteiner I. Patologicko-anatomický obraz hypertrofické kardiomyopatie. In: Veselka J, et al. Hypertrofická kardiomyopatie a příbuzná témata. Praha: Galén, 2006: 29-40.
  9. Gregor P, Veselka J. Hypertrofická kardiomyopatie. In: Aschermann M, et al. Kardiologie. Praha: Galén, 2004: 825-838.
  10. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol 1981; 48: 418-428. Go to original source... Go to PubMed...
  11. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114: 2232-2239. Go to original source... Go to PubMed...
  12. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104: 317-324. Go to original source... Go to PubMed...
  13. Beneš J, Gregor P, Mokráček A. Doporučení pro diagnostiku, léčbu a profylaxi infekční endokarditidy. Cor Vasa 2007; 49(6, Suppl K): 157-171.
  14. Maron B, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patiens with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: 2927-2933. Go to original source... Go to PubMed...
  15. Valeti US, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007; 49: 350-357. Go to original source... Go to PubMed...
  16. Sigwart U. Nonsurgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214. Go to original source... Go to PubMed...
  17. Veselka J. Některé změny v pohledu na léčbu hypertrofické obstrukční kardiomyopatie. Cor Vasa 1999; 41: 344-346.
  18. Veselka J, Duchoňová R, Procházková Š, et al. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablationfor hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004; 60: 133-135. Go to PubMed...
  19. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J 1999; 20: 1342-1354. Go to original source... Go to PubMed...
  20. Lawrenz T, Obergassel L, Lieder F, et al. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pace Pacing Clin Electrophysiol 2005; 28: 295-300. Go to original source... Go to PubMed...
  21. Simon RD, Crawford FA 3rd, Spencer WH 3rd, Gold MR. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2005; 28: 1354-1356. Go to original source... Go to PubMed...
  22. Batalis NI, Harley RA, Collins KA. Iatrogenic deaths following treatment for hypertrophic obstructive cardiomyopathy: case reports and an approach to the autopsy and death certification. Am J Forensic Med Pathol 2005; 26: 343-348. Go to original source... Go to PubMed...
  23. Brtko M, Šťásek J, Vojáček J, et al. Hypertrofická kardiomyopatie - současné možnosti léčby. Interv Akut Kardiol 2008; 7: 100-105.
  24. Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50: 831-834. Go to original source... Go to PubMed...
  25. Hess OM, Sigwart U. New treatment strategie for hypertrophic obstructive cardiomyopathy. Alcohol ablation of the septum: the new gold standard? J Am Coll Cardiol 2004; 44: 2054-2055. Go to original source... Go to PubMed...
  26. Cecchi F, Olivotto I, Betocchi S, et al. The italian registry for hypertrophic cardiomyopathy: a nationwide survey. Am Heart J 2005; 150: 947-954. Go to original source... Go to PubMed...
  27. Smedira NG, Lytle BW, Lever HM, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2008; 85: 127-134. Go to original source... Go to PubMed...
  28. Faber L, Seggewiss H, Welge D, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiography 2004; 5: 347-355. Go to original source... Go to PubMed...
  29. Minakata K, Dearani JA, Schaff HV, et al. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 2005; 80: 851-856. Go to original source... Go to PubMed...
  30. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 470-476. Go to original source... Go to PubMed...
  31. Chang SM, Nagueh SF, Spencer WH, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003; 42: 296-300. Go to original source... Go to PubMed...
  32. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005; 111: 2033-2041. Go to original source... Go to PubMed...
  33. Firoozi S, Elliott PM, Sharma S, et al. Septal myotomymyectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002; 23: 1617-1624. Go to original source... Go to PubMed...
  34. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001; 38: 1994-2000.
  35. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-1706. Go to original source... Go to PubMed...
  36. Sitges M, Shiota T, Lever HM, et al. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 2003; 91: 817-821. Go to original source... Go to PubMed...
  37. Durand E, Mousseaux E, Coste P, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J 2008; 29: 348-355. Go to original source... Go to PubMed...
  38. Trehan V, Mukhopadhyay S, Rangasetty UC. Percutaneous transseptal myocardial ablation with wire (PTSAW): a new technique. J Invas Cardiol 2004; 16: 204-206.
  39. Seggewiss H, Faber L. Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiography 2000; 1: 277-280. Go to original source... Go to PubMed...
  40. Tengiz I, Ercan E, Alioglu E, Turk UO. Percutaneous septal ablation for left mid-ventricular obstructive hypertrophic cardiomyopathy: a case report. BMC Cardiovascular Disorders 2006; 6: 15. Go to original source... Go to PubMed...
  41. Qin JX, Shiota, Lever HM, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol 2004; 93: 171-175. Go to original source... Go to PubMed...
  42. Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999; 99: 344-347. Go to original source... Go to PubMed...
  43. Jassal DS, Neilan TG, Fifer MA, et al. Sustained improvement in left venricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Hear J 2006; 27: 1805-1810. Go to original source... Go to PubMed...
  44. McLeod ChJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007; 28: 2583-2588. Go to original source... Go to PubMed...
  45. Elliott PM, Gimero JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27: 1933-1941. Go to original source... Go to PubMed...
  46. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008; 118: 131-139. Go to original source... Go to PubMed...
  47. Sorraja P, Nishimura RA, Gersh BJ, et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. J Am Coll Cardiol 2009; 54: 234-241. Go to original source... Go to PubMed...
  48. Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44: 2044-2053. Go to original source... Go to PubMed...
  49. Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 2005; 129: 351-358. Go to original source... Go to PubMed...
  50. Talreja DR, Nishimura RA, Edwards WD, et al. Alcohol septal ablation versus surgical septal myectomy. Comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 2004; 44: 2329-2332. Go to original source... Go to PubMed...
  51. van der Lee C, ten Cate FJ, Geleijnse ML, et al. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation 2005; 112: 482-488. Go to original source... Go to PubMed...
  52. Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy - alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J 2009; 30: 1080-1087. Go to original source... Go to PubMed...
  53. Leonardi S, Raineri C, De Ferrari GM, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30: 2003-2010. Go to original source... Go to PubMed...
  54. Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy - the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007; 4(9): 503-512. Go to original source... Go to PubMed...
  55. Joyce FS, Lever HM, Cosgrove DM 3rd. Treatment of hypertrophic cardiomyopathy by mitral valve repair and septal myectomy. Ann Thorac Surg. 1994; 57(4): 1025-1027. Go to original source... Go to PubMed...
  56. Petrone RK, Klues HG, Panza JA, Peterson EE, Maron BJ. Coexistence of mitral valve prolapse in a consecutive group of 528 patients with hypertrophic cardiomyopathy assessed with echocardiography. J Am Coll Cardiol. 1992; 20(1): 55-61. Go to original source... Go to PubMed...
  57. Delmo Walter EM, Siniawski H, Hetzer R. Sustained improvement after combined anterior mitral valve leaflet retention plasty and septal myectomy in preventing systolic anterior motion in hypertrophic obstructive cardiomyopathy in children. Eur J Cardiothorac Surg. 2009; 36(3): 546-552. Go to original source... Go to PubMed...
  58. van der Lee C, Kofflard MJ, van Herwerden LA, Vletter WB, ten Cate FJ. Sustained improvement after combined anterior mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy. Circulation. 2003; 108(17): 2088-2092. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.